Enliven Therapeutics Inc (ELVN)

$24.65

-0.45

(-1.79%)

Market is closed - opens 7 PM, 17 Jul 2024

Performance

  • $24.49
    $25.13
    $24.65
    downward going graph

    0.67%

    Downside

    Day's Volatility :2.57%

    Upside

    1.91%

    downward going graph
  • $9.80
    $26.00
    $24.65
    downward going graph

    60.24%

    Downside

    52 Weeks Volatility :62.31%

    Upside

    5.19%

    downward going graph

Returns

PeriodEnliven Therapeutics IncIndex (Russel 2000)
3 Months
42.49%
0.0%
6 Months
119.31%
0.0%
1 Year
32.53%
0.0%
3 Years
3.79%
-18.2%

Highlights

Market Capitalization
996.7M
Book Value
$6.79
Earnings Per Share (EPS)
-1.75
Wall Street Target Price
34.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-17.52%
Return On Equity TTM
-26.14%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-90.2M
Diluted Eps TTM
-1.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.26
EPS Estimate Next Year
-2.77
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
-0.62

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Enliven Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 37.93%

Current $24.65
Target $34.00

Technicals Summary

Sell

Neutral

Buy

Enliven Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Enliven Therapeutics Inc
Enliven Therapeutics Inc
14.33%
119.31%
32.53%
3.79%
3.79%
Moderna, Inc.
Moderna, Inc.
-9.25%
24.7%
2.07%
-60.09%
791.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.75%
17.85%
51.74%
87.1%
265.7%
Novo Nordisk A/s
Novo Nordisk A/s
0.36%
32.05%
75.05%
218.96%
483.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.23%
12.73%
36.59%
145.42%
176.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Enliven Therapeutics Inc
Enliven Therapeutics Inc
NA
NA
NA
-2.26
-0.26
-0.18
NA
6.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.94
31.94
1.46
44.22
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.76
48.76
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
17.07
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Enliven Therapeutics Inc
Enliven Therapeutics Inc
Buy
$996.7M
3.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
791.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.2B
265.7%
31.94
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$633.1B
483.19%
48.76
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
176.04%
31.85
39.46%

Insights on Enliven Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 75.0% return, outperforming this stock by 42.5%

Company Information

enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.

Organization
Enliven Therapeutics Inc
Employees
50
CEO
Mr. Samuel S. Kintz M.B.A.
Industry
Miscellaneous

FAQs